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COMMENT&RESPONSE
Inappropriate Grading of Adverse Events
in Cancer Clinical Trials
To the Editor Consideration of toxic effects is a critical part of
cancer treatment. Therefore, the grading and reporting of all
gradesofadverseevents, especiallyhigh-gradeadverseevents,
must be standardized to allow for consistency and compari-
son across trials. The Common Terminology Criteria for Ad-
verse Events (CTCAE) has been widely used for reporting of
adverse events in oncology journals and at meetings.1
The recent study by Cristina et al2 demonstrated that
womenwith colorectal cancer receiving chemotherapy had a
clinically relevant greater risk of nonhematologic and objec-
tivelymeasureablehematologicadverseeventscomparedwith
men.Theauthors reported that, in2974patients receivingche-
motherapy, 18 women (1.4%) vs 6 men (0.4%) had grade 3 or
4 alopecia (P < .003).2However, in theCTCAE,whichwas also
used for grading adverse events in this important trial, the
maximum grade for alopecia is grade 2. Thus, this is one ex-
ample of the misuse of CTCAE and should be corrected
immediately.1
In our previous study, we found that a substantial pro-
portion of contemporary cancer clinical trials use inappro-
priate grading and reporting of adverse events that does not
conform to CTCAE.1,3 This situation is more urgent for trials
evaluating toxic effects data, such as the study by Cristina
et al.
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In Reply We thank Dr Zhang and colleagues for their com-
ment regarding the grading of adverse events in the phase 3
PETACC-3 trial, which compared biweekly infusional
fluorouracil/leucovorin alone or in combination with irino-
tecan as adjuvant treatment of stage 3 colon cancer.1 We
agree with Dr Zhang that the quality of adverse event grad-
ing is a critical issue in clinical trials, especially when evalu-
ating factors influencing toxic effects. However, in contrast
to what Zhang and colleagues assume, the investigators of
the PETACC-3 trial1 graded alopecia correctly as mentioned
in our article2; adverse events were graded according to the
National Cancer Institute of Canada Common Toxicity Grad-
ing expanded common toxicity criteria (version revised in
May 1991, which was detailed in the PETACC-3 protocol but
is no longer available for reference). In this version, alopecia
is graded from grade 1 (mild hair loss) to grade 3 (total body
hair loss). Therefore, no correction is needed; in 2974
patients receiving chemotherapy, 1.4% of women vs 0.4% of
men presented with an alopecia grade greater than 2.2 It is
in the Common Toxicity Criteria version 2.0 and later that
alopecia was graded as either grade 1 (mild hair loss) or
grade 2 (pronounced hair loss).3 Moreover, we would like to
mention that, regardless of the number of categories in
which alopecia is graded, a bias in the comparative assess-
ment of the severity of alopecia between men and women is
likely to be introduced by differences in baseline condition,
with men more often having alopecia at baseline. Further-
more, sex differences in the subjective perception of the
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severity of alopecia might also contribute to a bias because
women might pay more attention to their hair loss. How-
ever, the significant differences in neutropenia described in
our article clearly indicate that significant sex differences
are present in chemotherapy toxic effects, including objec-
tively measurable toxic effects.
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Assessing the Prognostic Value of the Automated
Bone Scan Index for Prostate Cancer
To the Editor Armstrong and colleagues1 conducted an impor-
tant study to assess the use of the automated Bone Scan In-
dex (aBSI) as a tool inpredicting, amongotheroutcomes, over-
all survival (OS) in patients with metastatic prostate cancer.
As a continuous prediction score, the aBSI’s hazard ratio (HR)
for OS was statistically significant, with a lower aBSI associ-
atedwith better survival.However, evaluations basedonHRs
are difficult to interpret clinically.2-4 Moreover, the concor-
dance index for thediscriminative ability of the aBSIwas only
0.63, which suggests that the continuous aBSI score may not
be an effective prediction tool at the individual patient level.
In practice, onemay use the aBSI to stratify patients into sev-
eral ordered categories. When stratifying by quartiles of the
aBSI score, Armstrong and colleagues1 reportedobservedme-
dian OS times (lowest to highest aBSI quartiles) of 34.7, 27.3,
21.7, and 13.3 months, respectively. These values appear to
demonstrate the clinically interpretable discriminative abil-
ity of the stratified aBSI. Unfortunately, statistical inference
for median times across strata was not provided. To further
investigate, we generated 95%CIs ofmedian OS times for pa-
tients in quartile 1 to quartile 4 using reconstructed data from
theKaplan-Meier curves inFigure2A.1 SomeCIs (quartile2and
quartile 3) overlapped.That is, the truemedianOS timesofpa-
tients in quartile 2 and quartile 3may be identical, suggesting
that the stratified aBSImay lackdiscriminative capability. The
wide, overlapping CIs likely resulted from unstable median
time estimates.
An alternative assessment method for the discrimina-
tive ability of aBSI may be based on restricted mean survival
times (RMST).2-4 The RMSTs for 36-month follow-up are
26.4, 24.7, 21.9, and 16.0 months. The difference between
quartile 1 and quartile 4 is 10.4 months (95% CI, 8.0-12.8
months; P < .001); the difference between quartile 2 and
quartile 4 is 8.8 months (95% CI, 6.3-11.2 months; P < .001);
and the difference between quartile 3 and quartile 4 is 6.0
months (95% CI, 3.5-8.4 months; P < .001). Over a
36-month follow-up period, a patient with an aBSI in quar-
tile 1 would live for 26.4 months on average. Moreover, a
patient with an aBSI in quartile 1 would, on average, live for
10.4 more months than a patient with an aBSI in quartile 4.
The RMST provides a clinically and statistically informative
assessment of the stratified aBSI.
In predictive medicine, one usually generates several
categories/strata from a continuous score system to con-
struct a stratification procedure. A desirable stratification
scheme would possess small intrastratum variation and
clinically meaningful discriminatory capability across
strata. The usual practice of using score quartiles to group
patients may be suboptimal. This issue has been discussed
and alternatives have been proposed in a recently published
study.5
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In Reply We thank Sun and colleagues for their interest and
comments regarding our work.1 We agree that restricted
mean survival time (RMST) analysis is a recent and valuable
Letters
270 JAMAOncology February 2019 Volume 5, Number 2 (Reprinted) jamaoncology.com
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Université de Lausanne User  on 01/10/2020
